Meðferð lifrarbólgu C með peg-interferóni og ríbavíríni á Íslandi 2002-2012 | Zendy

Benedikt Friðriksson | Zendy; Ottar M. Bergmann | Zendy; Sigurður Ólafsson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Meðferð lifrarbólgu C með peg-interferóni og ríbavíríni á Íslandi 2002-2012

Author(s) -

Benedikt Friðriksson,

Ottar M. Bergmann,

Sigurður Ólafsson

Publication year - 2017

Publication title -

læknablaðið

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.147

H-Index - 12

eISSN - 1670-4959

pISSN - 0023-7213

DOI - 10.17992/lbl.2017.03.126

Subject(s) - medicine , cirrhosis , ribavirin , genotype , gastroenterology , pegylated interferon , genotyping , hepatitis c virus , hepatitis c , population , sofosbuvir , immunology , virus , biology , biochemistry , environmental health , gene

Hepatitis C is a major cause of chronic liver disease and cirrhosis in Western countries. Its treatment aims at eradicating the virus and patients are considered cured if the virus is undetectable by PCR in blood 12-24 weeks after end of treatment (sustained virological response, SVR). The aim of this study is to investigate the results of treating hepatitis C in Iceland during the period 2002-2012.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research